Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.75 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20151824 | 0.86 | MGLL (1.00) | MGLLCYP2D6 | |
| SCHEMBL29561180 | 0.85 | MGLL (0.56) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL20137027 | 0.85 | MGLL (0.56) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL20151875 | 0.80 | MGLL (0.65) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL20151867 | 0.79 | TSHR (0.58) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL20137044 | 0.78 | CYP2D6 (0.54) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL28936361 | 0.78 | MGLL (0.47) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL21571740 | 0.78 | MGLL (0.54) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL447202 | 0.78 | CYP2D6 (0.53) | MGLLTSHRCYP2D6TACR1USP2 | |
| SCHEMBL19974330 | 0.78 | CYP2D6 (0.53) | MGLLTSHRCYP2D6TACR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885TSHR 4772/4885CYP2D6 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.